CMPX (Compass Therapeutics) Cash Flow for Lease Financing: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMPX Compass Therapeutics Inc CMPX
26 GF Score
Price $2.31
! 2 Warning Signs
View Full Analysis

What is Compass Therapeutics Cash Flow for Lease Financing?

Compass Therapeutics CMPX -2.53% 26 Cash Flow for Lease Financing is $0.00 Mil as of Jun. 2026. GuruFocus rates CMPX with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Compass Therapeutics's Cash Flow for Lease Financing for the three months ended in Jun. 2026 was $0.00 Mil. Compass Therapeutics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Mar. 2026 ), Compass Therapeutics's Cash Flow for Lease Financing remained the same in Jun. 2026 ($0.00 Mil).

Compass Therapeutics Cash Flow for Lease Financing Historical Data

* Premium members only.

The historical data trend for Compass Therapeutics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Therapeutics Cash Flow for Lease Financing Chart

Compass Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Lease Financing
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Compass Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CMPX
26GF Score
Compass Therapeutics Inc CMPX
Cash Flow for Lease Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Therapeutics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Lease Financing of $0.00 Mil mean?
Compass Therapeutics (CMPX) has a Cash Flow for Lease Financing of $0.00 Mil as of Jun. 2026. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on Compass Therapeutics and its competitors.
Is Compass Therapeutics' Cash Flow for Lease Financing too high?
Compass Therapeutics' current Cash Flow for Lease Financing is $0.00 Mil. Overall, Compass Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' Cash Flow for Lease Financing compare to ARCT and AVIR?
Compass Therapeutics' Cash Flow for Lease Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Lease Financing for a Biotechnology company?
A good Cash Flow for Lease Financing depends on the Biotechnology industry context. However, Cash Flow for Lease Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Lease Financing mean?
A high Cash Flow for Lease Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on Compass Therapeutics and its competitors. Compass Therapeutics's current Cash Flow for Lease Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current Cash Flow for Lease Financing of $0.00 Mil. The current Cash Flow for Lease Financing is $0.00 Mil. Compass Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Lease Financing calculated?
Cash Flow for Lease Financing is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current Cash Flow for Lease Financing is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Therapeutics Business Description

Address 80 Guest Street, Suite 601, Boston, MA, USA, 02135
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
26GF Score

Get the complete analysis for CMPX

Cash Flow for Lease Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.31
Price